Skip to main content
Log in

Effects of Cytoflavin and its Components on Behavioral Disorders in Mice with Alloxan Diabetes

  • MOLECULAR BIOLOGY PROBLEMS OF DRUG DESIGN AND MECHANISM OF DRUG ACTION
  • Published:
Pharmaceutical Chemistry Journal Aims and scope

The effects of the combined formulation Cytoflavin and its individual components (meglumine sodium succinate, nicotinamide, riboflavin, and inosine) on depressive behavioral disorders (DBD) were studied in mice with alloxan diabetes. Cytoflavin was found to be effective in correcting deficits in the activity of animals in the open field test and significantly reduced “despair behavior” in a 6-min tail suspension test; it also produced a transient hypoglycemic effect. The DBD-correcting activity of Cytoflavin was shown to be associated mainly with meglumine sodium succinate. The effect was significantly less linked with nicotinamide, which also produced the transient hypoglycemic action of Cytoflavin. Riboflavin made an even smaller contribution to the positive psychotropic action of Cytoflavin. The most problematic component of Cytoflavin was inosine, courses of which significantly increased lethality in mice with alloxan diabetes. However, this effect of inosine was only apparent when used alone, and disappeared completely when used in Cytoflavin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. S. A. Rumyantseva, A. I. Fedin, S. B. Bolevich, et al., Zh. Nevrol. Psikhiat., 110(8), 16 – 21 (2010).

    Google Scholar 

  2. E. V. Silina and S. A. Rumyantseva, Vest. Intensiv. Ter., No. 2, 82 – 88 (2006).

  3. S. V. Okovityi, D. S. Sukhanov, V. A. Zaplutanov, et al., Klin. Med., No. 9, 63 – 68 (2012).

  4. I. A. Volchegorskii, L. M. Rassokhina, and I. Yu. Miroshnichenko, Éksperim. Klin. Farmakol., 5, 17 – 25 (2011).

    Google Scholar 

  5. I. A. Volchegorskii, L. M. Rassokhina, and I. Yu. Miroshnichenko, Byull. Éksperim. Biol. Med., No. 1, 63 – 70 (2013).

  6. R. A. Kopaladze, Usp. Fiziol. Nauk., 29(4), 74 – 92 (1998).

    CAS  PubMed  Google Scholar 

  7. I. A. Volchegorskii, I. I. Dolgushin, O. L. Kolesnikov, and V. E. Tseilikman, Experimental Modeling and Laboratory Evaluation of the Body’s Adaptive Reactions [in Russian], Chelyabinsk State Pedagogical University, Chelyabinsk (2000).

    Google Scholar 

  8. L. Steru, Psychopharmacology, 85, 367 – 370 (1985).

    Article  CAS  PubMed  Google Scholar 

  9. I. A. Volchegorskii, L. M. Rassokhina, and I. Yu. Miroshnichenko, Probl. Éndokrinol., No. 4, 20 – 24 (2009).

  10. I. A. Volchegorskii, L. M. Rassokhina, and I. Yu. Miroshnichenko, Éksperim. Klin. Farmakol., 72(2), 11 – 15 (2009).

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 48, No. 3, pp. 3 – 8, March, 2014.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Volchegorskii, I.A., Rassokhina, L.M. & Ermakova, S.G. Effects of Cytoflavin and its Components on Behavioral Disorders in Mice with Alloxan Diabetes. Pharm Chem J 48, 143–148 (2014). https://doi.org/10.1007/s11094-014-1066-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-014-1066-y

Keywords

Navigation